Study Name:
TCR001-201 Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
Targeted Disease(s):
Lung Cancer
Purpose of Study:
To evaluate the objective response rate (ORR) (RECIST and iRECIST criteria) of subjects with solid cancers who receive TCR-T cell drug product, define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of T-Cell Receptor T cells, and evaluate the feasibility of TCR-T cell drug product manufacturing.Study Dates:
January 1, 2022 - January 1, 2025
Study Design:
Controlled Design
Study Location:
TX
Lead Institution:
MD Anderson Cancer Center
Funding Source:
Alaunos Therapeutics
Contact:
Phone: 855-552-5389Email: GIClinicalTrials@mdanderson.org
ClinicalTrails.gov Identifier:
NCT05194735
